These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21031373)

  • 1. Interaction of the human prion protein PrP106-126 with metal complexes: potential therapeutic agents against prion disease.
    Wang Y; Xu J; Wang L; Zhang B; Du W
    Chemistry; 2010 Dec; 16(45):13339-42. PubMed ID: 21031373
    [No Abstract]   [Full Text] [Related]  

  • 2. Copper(II) interaction with unstructured prion domain outside the octarepeat region: speciation, stability, and binding details of copper(II) complexes with PrP106-126 peptides.
    Di Natale G; Grasso G; Impellizzeri G; La Mendola D; Micera G; Mihala N; Nagy Z; Osz K; Pappalardo G; Rigó V; Rizzarelli E; Sanna D; Sóvágó I
    Inorg Chem; 2005 Oct; 44(20):7214-25. PubMed ID: 16180886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modelling indicates that the pathological conformations of prion proteins might be beta-helical.
    Downing DT; Lazo ND
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):453-60. PubMed ID: 10510313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of gold-bipyridyl derivants on aggregation and disaggregation of the prion neuropeptide PrP106-126.
    Zhao C; Wang X; He L; Zhu D; Wang B; Du W
    Metallomics; 2014 Nov; 6(11):2117-25. PubMed ID: 25273168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theoretical study of the prion protein based on the fragment molecular orbital method.
    Ishikawa T; Ishikura T; Kuwata K
    J Comput Chem; 2009 Dec; 30(16):2594-601. PubMed ID: 19408278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered toxicity of the prion protein peptide PrP106-126 carrying the Ala(117)-->Val mutation.
    Brown DR
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):785-91. PubMed ID: 10698707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrP106-126 peptide disrupts lipid membranes: influence of C-terminal amidation.
    Zheng W; Wang L; Hong Y; Sha Y
    Biochem Biophys Res Commun; 2009 Feb; 379(2):298-303. PubMed ID: 19103159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clustered negative charges on the lipid membrane surface induce beta-sheet formation of prion protein fragment 106-126.
    Miura T; Yoda M; Takaku N; Hirose T; Takeuchi H
    Biochemistry; 2007 Oct; 46(41):11589-97. PubMed ID: 17887730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gold complexes inhibit the aggregation of prion neuropeptides.
    Wang X; He L; Zhao C; Du W; Lin J
    J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons.
    White AR; Guirguis R; Brazier MW; Jobling MF; Hill AF; Beyreuther K; Barrow CJ; Masters CL; Collins SJ; Cappai R
    Neurobiol Dis; 2001 Apr; 8(2):299-316. PubMed ID: 11300725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the human prion PrP(106-126) sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies.
    Gaggelli E; Bernardi F; Molteni E; Pogni R; Valensin D; Valensin G; Remelli M; Luczkowski M; Kozlowski H
    J Am Chem Soc; 2005 Jan; 127(3):996-1006. PubMed ID: 15656638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper(II) complexes with peptide fragments encompassing the sequence 122-130 of human doppel protein.
    Mendola DL; Magrì A; Hansson O; Bonomo RP; Rizzarelli E
    J Inorg Biochem; 2009 May; 103(5):758-65. PubMed ID: 19237200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocytic regulation of NMDA receptor subunit composition modulates the toxicity of prion peptide PrP106-126.
    Sassoon J; Daniels M; Brown DR
    Mol Cell Neurosci; 2004 Jan; 25(1):181-91. PubMed ID: 14962751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds.
    Boshuizen RS; Langeveld JP; Salmona M; Williams A; Meloen RH; Langedijk JP
    Anal Biochem; 2004 Oct; 333(2):372-80. PubMed ID: 15450815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes.
    Wang X; Zhang B; Zhao C; Wang Y; He L; Cui M; Zhu X; Du W
    J Inorg Biochem; 2013 Nov; 128():1-10. PubMed ID: 23911565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126.
    Kanapathipillai M; Ku SH; Girigoswami K; Park CB
    Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PrPSc-like prion protein peptide inhibits the function of cellular prion protein.
    Brown DR
    Biochem J; 2000 Dec; 352 Pt 2(Pt 2):511-8. PubMed ID: 11085945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin prevents aggregation of neuropeptide 106-126 in vitro.
    McHattie S; Edington N
    Biochem Biophys Res Commun; 1999 Jun; 259(2):336-40. PubMed ID: 10362509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative syntheses of peptides and peptide thioesters derived from mouse and human prion proteins.
    Sebestík J; Zawada Z; Safařík M; Hlaváček J
    Amino Acids; 2012 Sep; 43(3):1297-309. PubMed ID: 22212592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.